Bimagrumab is a monoclonal antibody targeting type II activin receptors. In a randomized phase 2 study, the combination of bimagrumab with semaglutide resulted in a weight loss of up to 17.8 kg. Semaglutide alone achieved a weight reduction of up to 14.2 kg[1][2]. In particular, the combination preserved lean mass while reducing visceral fat. The study demonstrated the potential of this combination for the effective treatment of obesity. The results were published in Nature Medicine online on March 2, 2026 (doi:10.1038/s41591-026-04204-0).